Ocera Therapeutics

Biopharma, Biotechnology, Therapeutics
Founded in 2005-01-01
Palo Alto, California, United States
http://www.ocerainc.com
For Profit

About Ocera Therapeutics

Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: 10 active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 97000150 USD
  • Last Funding: 20000000 USD (Post-IPO Debt)
  • Funding Status: M&A

Technology Stack

Ocera Therapeutics actively uses 10 products in their tech stack.

Market Presence

Industries: Biopharma, Biotechnology, Therapeutics

Headquarters: Palo Alto, California, United States